NCT07312227|Recruiting
Loading search results
Sponsor study identifier
observational
27
2 countries
2
Study Start
February 11, 2026
Actual (reported)Primary Completion
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
In this study, the investigators will follow two small cohorts of pregnant women: a cohort of healthy women with uncomplicated pregnancies residing at high altitude, a control group of healthy women with uncomplicated pregnancies residing at sea level, to characterize differences in cardiopulmonary adaptation and nitric oxide (NO) pathway expression at elevations \>3,500 m throughout pregnancy and into the postpartum period. The investigators aim to investigate right-sided cardiac impairment induced by chronic hypobaric hypoxemia, its effects on fetal growth, and the potential contribution of cardiovascular nitric oxide depletion to obstetric complications.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 3, 2025
Actual (reported)December 31, 2025
Actual (reported)February 11, 2026
Actual (reported)December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
February 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Pulmonary artery pressures
Measurement will be performed by transthoracic echocardiography.
Late pregnancy (35 ± 4 weeks gestation) and postpartum (6 ± 0.3 weeks)
Echographic estimate of fetal weight
Late pregnancy (35 ± 4 weeks gestation)
Nitric oxide metabolites
Measurement will be performed with a chemiluminescence assay.
Late pregnancy (35 ± 4 weeks gestation) and postpartum (6 ± 0.3 weeks) for maternal samples, at delivery (neonatal samples)
RV remodeling echocardiography parameters
Late pregnancy (35 ± 4 weeks gestation) and postpartum (6 ± 0.3 weeks)
Women with uncomplicated pregnancy.
Women with uncomplicated pregnancy.
The cohort of healthy pregnant women residing at high altitude will selected from pregnant women who have lived at an altitude greater than 3500 meters throughout pregnancy and at delivery. The control group will be pregnant women who have lived at sea level throughout pregnancy and at delivery.
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Hospital De La Meujer
La Paz, Bolivia
Maternal urine, blood samples, umbilical cord blood samples, placental tissue
Lorenzo Berra, MD
Massachusetts General Hospital
First Submitted
December 3, 2025
First Posted
December 31, 2025
Study Start
February 11, 2026
Actual (reported)Primary Completion
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Weight at birth
At delivery
Contact the study team to confirm eligibility.
Study Completion
February 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
May 26, 2026
Record last verified: 2026-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: